Assessing fluorquinolones as risk factor for musculoskeletal disorders in children: A systematic review and meta-analysis;Efectos adversos musculoesqueléticos por el uso de fluoroquinolonas en niños: Un metaanálisis

Archivos Argentinos de Pediatria

Volumn 108, Issue 6, 2010, Pages 524-531

  Rosanova, María Teresa ^a   Lede, Roberto ^a   Capurro, Haroldo ^a   Petrungaro, Virgilio ^a   Copertari, Pablo ^a  

^a Área de Evaluación de Tecnologías   (Argentina)

Author keywords

Arthropathy; Fluoroquinolones; Meta analysis; Tendinopathy

Indexed keywords

QUINOLONE DERIVATIVE;

ARTHROPATHY; CLINICAL TRIAL; COCHRANE LIBRARY; DRUG CONTRAINDICATION; HUMAN; MEDLINE; META ANALYSIS; MUSCULOSKELETAL DISEASE; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; TENDINITIS;

CHILD; FLUOROQUINOLONES; HUMANS; MUSCULOSKELETAL DISEASES; RISK FACTORS;

EID: 78649996230     PISSN: 03250075     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Schaad U. Role of the new quinolones in pediatric practice. Pediatr Infect Dis J 1992;11:1043-6.
2. Schaad U, Salam M, Aujard Y, Dagan R, et al. Use of fluoroquinolones in pediatrics: consensus report of an International Society of Chemotherapy commission. Pediatr Infect Dis J 1995;14:1-9.
3. Adam D. Use of quinolones in pediatric patients. Rev Inf Dis 1988;11:1113-6.
4. Stahlmann R. Safety profile of the quinolones. J Antimicrob Chemother 1990;26:31-44.
5. Shaad U, Sander E, Wedgwood J, Schaffner T. Morphologic studies for skeletal toxicity after prolonged ciprofloxacin therapy in two juvenile cystic fibrosis patients. Pediatr Infect Dis J 1992;11:1047-9.
6. Lumbiganon P, Pengasa K, Sookprane T. Ciprofloxacin in neonates and its possible adverse effect on the teeth. Pediatr Infect Dis J 1991;10:619-20.
7. Valerius M, Kosh C, holby N. Prevention of chronic Pseudomonas aeruginosa colonization in cystic fibrosis by early treatment. Lancet 1991;338:725-6.
8. Cross JT. Fluoroquinolones. Sem Pediat Infect Dis 2001;12:211-28.
9. h ansen L, Eshen C, Brunn B. Neonatal Salmonella meningitis. Two cases reports. Acta Pediatr 1996;85:629-35.
10. Andriole V. The quinolones: past, present and future. Clin Inf Dis 2005;2:3113-9.
11. Shaad U. Will fluoroquinolones ever be recommended for common infections in children? Pediatr Infect Dis J 2007; 26:865-7.
12. Grady R. Safety profile of quinolone antibiotics in the pediatric population. Pediatr Infect Dis J 2003;22:1128-32.
13. Leibovitz E. The use of fluoroquinolones in children. Current Opinion Pediatr 2006;18:64-70.
14. American Academy of Pediatrics. The use of systemic fluoroquinolones. Pediatrics 2006;3:1287-92.
15. Rosenthal R. Meta-analytic procedures for social research. Newbury: Sage; 1991.
16. Richard D, Nousia-Arvanitakis S, Sollich V, hampel B, et al. Oral ciprofloxacin vs intravenous ceftazidima plus tobramycin in pediatric cystic fibrosis: comparison of antipseudomonal efficacy and assesment of safety with ultrasonography and magnetic resonace imaging. Pediatr Infect Dis J 1997;16:572-8.
17. Leibovitz E, Janco J, Piglansky L, Press J, et al. Oral ciprofloxacine vs intramuscular ceftriaxone as empiric treatment of acute invasive diarrhea in children. Pediatr Infect Dis J 2004;19:1060-7.
18. Salam MA, Dhar U, Khan WA, Bennish ML. Randomised comparison of ciprofloxacin suspension and pivmecillinam for childhood shigellosis. Lancet 1998;352:522-7.
19. Bethell DB, hien TT, Phi LT, Day NP, et al. Effects on growth of single short courses of fluoroquinolones. Arch Dis Child 1996;74:44-6.
20. Yee CL, Duffy C, Gerbino PG, Stryker S, et al. Tendon or joint disorders in children after treatment with fluoroquinolones or azithromycin. Pediatr Infect Dis J 2002;21:525-9. (Pubitemid 34625833)
21. Chalumeau M, Tonnelier S, D'Athis P, Tréluyer JM, et al. Fluoroquinolone safety in pediatric patients: a prospective, multicenter, comparative cohort study in France. Pediatrics 2003;111:714-9.
22. Drossou-Agakdou V, Roilides E, PapakyriaKidou-Koliouska. P, Agakidis C, et al. Use of ciprofloxacin in neonatal sepsis: lack of adverse effects up to one year. Pediatr Infect Dis J 2004;23:346-50.
23. Uddin Ahmed N, Khan N, Saha S, Chowdhury A, et al. Ciprofloxacin treatment in preterm neonates in Bangladesh: lack of effects on growth and development. Pediatr Infect Dis J 2006;25:1137-41. (Pubitemid 44900677)
24. Nuutinen M, Turtinen J, Uhari M. Growth and joint symptoms in children treated with nalidixic acid. Pediatr Infect Dis J 1994;13:798-800. (Pubitemid 24286816)
25. Dutta S, Chowdhary G, Kumar P, Mukhopadhay K, et al. Ciprofloxacin administration to very low birth weight babies has no effect on linear growth in infancy. J Trop Pediatr 2006;52:103-6.
26. Warren RW. Rheumatologic aspects of pediatric cystic fibrosis patients treated with fluoroquinolones. Pediatr Infect Dis J 1997;16:118-22.
27. Shaad U. Clinical radiologic and magnetic resonance monitoring for skeletal toxicity in pediatric patients with cystic fibrosis receiving a 3 months of cipro. Pediatr Infect Dis J 1991;10:723-9.
28. Burkhard JE, Walterspiel JN, Shaad UB. Quinolone arthropathy in animals versus children. Clin Infect Dis 1997;25:1196-1204.
29. Forsythe C, Ernst M. Do fluoroquinolones commonly cause arthropathy in children? 2007;9:459-62.
30. Kubin R. Safety and efficacy of ciprofloxacin in paediatric patients-review. Infection 1993;21:413-21.